Know Cancer

forgot password

NMP22 Provides Improved Sensitivity in Detecting Bladder Cancers

18 Years
Open (Enrolling)
Bladder Cancer

Thank you

Trial Information

NMP22 Provides Improved Sensitivity in Detecting Bladder Cancers

Patients who have been previously treated for bladder cancer and are at a high risk for
recurrence are being monitored for recurrence every 3 months with urine cytology and
cystoscopy as part of standard care.The NMP22 Bladder Cancer ® Test Kit has been designed to
provide an alternative to regular urine cytology. A urine sample will be provided and
divided with a portion being used to assess the NMP22 test kit and the remaining sample to
be sent to the lab for regular urine cytology. Patient charts will be reviewed by a medical
student to record age, clinical stage, pathologic stage, time to disease
progression/recurrence, site of recurrence and survival data.

Inclusion Criteria:

- · History of pTis, pT1, large (>2cm) pTa or multiple pTa bladder cancer tumours.

Written Informed Consent prior to any study-related procedures.

Exclusion Criteria:

- History of bladder cancer tumours other than those listed in inclusion

Type of Study:


Study Design:

Observational Model: Cohort, Time Perspective: Prospective

Principal Investigator

Jonathan Izawa, MD FRCSC

Investigator Role:

Principal Investigator

Investigator Affiliation:

University of Western Ontario, Canada


Canada: Ethics Review Committee

Study ID:




Start Date:

January 2006

Completion Date:

January 2009

Related Keywords:

  • Bladder Cancer
  • Detection of Bladder Cancer using NMP22 Urine Test Kit
  • Urinary Bladder Neoplasms